Neurolixis Inc. is delighted to announce the appointment of Mark H.N. Corrigan as a member of its Advisory Board.
Dr. Corrigan has profound understanding of drug develoment and clinical trials strategy in the pharmaceutical and biotechnology environment and possesses extensive management experience in several large pharmaceutical companies. Dr. Corrigan's deep knowledge of CNS research and development will provide valuable insights and facilitate the advancement of the Neurolixis programs.
See more information concerning Neurolixis' team here.